Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV002511149 | SCV002820936 | pathogenic | Glanzmann thrombasthenia | 2022-04-07 | reviewed by expert panel | curation | The NM_000419.5(ITGA2B):c.337C>T (p.Gln113Ter) variant in exon 3/30 is a nonsense variant predicted to lead to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). At least one patient (reported via personal communication with Dr. Jose Rivera, Servicio de Hematolog_x0019_ıa y Oncolog_x0019_ıa Me_x0019_dica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonacio_x0019_n, Universidad de Murcia) with this variant (in combination with c.2150T>C (p.Leu717Pro)) displayed mucocutaneous bleeding and impaired aggregation with all agonists except ristocetin, which is highly specific for Glanzmann thrombasthenia. Additionally, αIIbβ3 surface expression was absent, as measured by flow cytometry and Western blot, and ITGA2B and ITGB3 were sequenced across all exons and intron/exon boundaries (PP4_Strong). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). In summary this variant meets criteria to be classified as Pathogenic for autosomal recessive Glanzmann Thrombasthenia based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: PVS1, PP4_Strong, PM2_Supporting. (VCEP specifications version 2; date of approval 03/15/2022) |
ISTH- |
RCV002281026 | SCV002569354 | uncertain significance | Glanzmann thrombasthenia 1 | criteria provided, single submitter | clinical testing |